| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | FH535 | GDSC1000 | pan-cancer | AAC | -0.009 | 0.8 |
| mRNA | XL765 | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | ML334 diastereomer | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.015 | 0.8 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | -0.0088 | 0.8 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | BRD1835 | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | temsirolimus | FIMM | pan-cancer | AAC | 0.039 | 0.8 |
| mRNA | EHT 1864 | GDSC1000 | pan-cancer | AAC | 0.0084 | 0.8 |
| mRNA | regorafenib | CTRPv2 | pan-cancer | AAC | 0.0098 | 0.8 |